Microvascular Health Solutions Announces High-Intensity Interval Exercise Study Using Its’ Testing Device GlycoCheck

CHATTANOOGA, TENNESSEE, USA, August 17, 2022 – Microvascular Health Solutions, LLC (MVHS), a BioRegenx subsidiary based in Alpine, Utah, announces that a new peer-reviewed study has been published using GlycoCheck, a medical testing device, exclusively distributed worldwide by MVHS. The study, titled Effects of high-intensity interval training on microvascular glycocalyx and associated microRNAs, looked at how high-intensity interval training (HIIT) affects the microvasculature including the endothelial glycocalyx. The study was published by the American Journal of Physiology, and it was authored by researchers at the University Hospital Muenster, Germany.

The study evaluated the effects of physical fitness and physical exercise on microvascular parameters including glycocalyx thickness and associated miRNAs in young healthy adults. The researchers found that maximal exercise capacity was positively associated with microvascular glycocalyx thickness at baseline. Moreover, glycocalyx thickness increased with the improvement in exercise capacity postintervention, and the increase in glycocalyx thickness was predicted by acute elevation of miRNA-143 levels.

The researchers found significant associations of microvascular glycocalyx thickness and physical fitness in healthy young subjects. Furthermore, glycocalyx thickness and number of perfused vessels changed in accordance with exercise performance after a 4-wk HIIT program. To the best of their knowledge, data on long-term changes in microvascular structures, including glycocalyx thickness induced by HIIT as reported in the study, are so far missing from the literature. They conclude that HIIT may be performed to induce microvascular changes and increase glycocalyx thickness. While noninvasive sublingual microvascular imaging might be a useful tool to monitor vasculoprotective exercise effects, the herein-described associations with specific miRNA changes at the beginning of the training intervention might lead to the identification of circulating miRNAs to predict beneficial microvascular changes.

“This paper reinforces the need for people to engage in a regular exercise regimen to promote good health,” said Robert M. Long, co-founder and CEO of MVHS and Chairman of the Board of BioRegenx and “Combining exercise with MVHS’s nutraceutical Endocalyx Pro™, shown in studies to improve microvascular health, can be especially impactful for athletes and anyone of any age who wants to improve their body’s performance.”
Dr. Hans Vink, Chief Science Officer of BioRegenx is of the world’s leading researchers of endothelial glycocalyx health, said “as someone who runs for exercise and who has a high MicroVascular Health Score™, this study offers substantiation that high-intensity cardio training improves the robustness of the glycocalyx.” Dr. Vink was the inventor of the GlycoCheck medical testing device and a co-founder of GlycoCheck.

About BioRegenx

BioRegenx, Inc., (BioRegenx.com) a holding company, is the parent company of three wholly owned subsidiaries, Microvascular Health Solutions, LLC, My Body Rx, LLC, and NuLife Sciences, Inc. BioRegenx and its subsidiaries combine the patented intellectual property of the breakthrough GlycoCheck medical testing device, the patented nutraceutical Endocalyx Pro, additional synergistic dietary supplement products sold under the My Body Rx brand, and a customer base of medical professionals and brand partners throughout North America.

Safe Harbor

This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding potential sales, the success of the company’s business, as well as statements that include the word believe or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of BioRegenx, Inc. to differ materially from those implied or expressed by such forward-looking statements. This press release speaks as of the date first set forth above, and BioRegenx, Inc. assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, timely development of products, inability to deliver products when ordered, inability of potential customers to pay for ordered products, and political and economic risks inherent in international trade.